TMCnet

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s ( ...
GEN

Cellino, Karis Bio Partner on Autologous iPSC-Based Therapy for Cardiovascular Disease

Cellino, a biotechnology firm working on autonomous biomanufacturing for personalized regenerative medicines, has signed a strategic collaboration with Karis Bio, a South Korean cell therapy company, ...
Rutland Herald

Kincell Bio Announces Strategic Expansion of Research Triangle Park Facility to Support Late-Stage and Commercial Cell Therapy Manufacturing Programs

Kincell Bio, a leading contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell ...
Seeking Alpha

Allogene: I Am Less Sanguine About Allogeneic CAR-T's Prospects Than Before

Lest we forget with all the C-suites leaving, Allogene Therapeutics, Inc. (ALLO), as its name implies, is a leader in the development of allogeneic CAR-T therapies, or life-saving cell therapies ...
MM&M

Becoming ‘biologic-like’: CAR-T makers on quest to scale drugs’ production

Let’s take things back to the summer of 2017. At that time, Pascal Touchon joined Novartis to take over all commercial activities surrounding a first-of-it kind, cell-based gene therapy for cancer. By ...
Supply Chain

Five Key Manufacturing Challenges in Autologous Commercial Cell and Gene Therapies

Analyst Insight: Cell and gene therapies (CGT) provide highly personalized solutions for previously incurable genetic conditions and chronic diseases. While allogeneic CGT relies on a source of cells ...
GEN

How TC BioPharm Cut 200 Manufacturing Steps and Improved Products

TC BioPharm eliminated approximately 200 steps from its allogeneic CAR-T biomanufacturing process, reducing hands-on manufacturing time by half and cutting production costs to a fraction of the ...